Stockscreener 앱 받기
1.6807
0.89%
0.0007
전일 마감가:
$1.68
열려 있는:
$1.69
하루 거래량:
144.40K
Relative Volume:
0.12
시가총액:
$130.76M
수익:
$257.24M
순이익/손실:
$-237.89M
주가수익비율:
-0.6464
EPS:
-2.6
순현금흐름:
$-175.17M
1주 성능:
+5.94%
1개월 성능:
+3.35%
6개월 성능:
+54.09%
1년 성능:
+134.44%
1일 변동 폭
$1.68
$1.72
1주일 범위
$1.59
$1.805
52주 변동 폭
$0.6603
$2.43
Coherus Oncology Inc Stock (CHRS) Company Profile
명칭
Coherus Oncology Inc
전화
(650) 649-3530
주소
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
CHRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
1.685 | 195.26M | 257.24M | -237.89M | -175.17M | -2.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.65 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
638.50 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.80 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.69 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.38 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-04 | 업그레이드 | Maxim Group | Hold → Buy |
| 2024-08-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-11-17 | 개시 | Robert W. Baird | Outperform |
| 2023-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2023-07-24 | 개시 | Citigroup | Buy |
| 2023-05-01 | 개시 | Truist | Buy |
| 2023-03-28 | 업그레이드 | UBS | Neutral → Buy |
| 2022-06-14 | 개시 | UBS | Neutral |
| 2022-03-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-07-16 | 개시 | BofA Securities | Neutral |
| 2020-04-17 | 개시 | SunTrust | Buy |
| 2019-08-13 | 개시 | Mizuho | Buy |
| 2019-08-02 | 재확인 | H.C. Wainwright | Buy |
| 2019-08-02 | 재확인 | Maxim Group | Buy |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-05-07 | 개시 | H.C. Wainwright | Buy |
| 2018-08-28 | 개시 | H.C. Wainwright | Buy |
| 2018-03-09 | 재확인 | Maxim Group | Buy |
| 2017-08-08 | 재확인 | JP Morgan | Overweight |
| 2017-06-13 | 재확인 | Maxim Group | Buy |
| 2017-05-05 | 개시 | BMO Capital Markets | Outperform |
| 2016-10-19 | 개시 | Robert W. Baird | Outperform |
| 2016-09-07 | 개시 | Maxim Group | Buy |
| 2016-07-27 | 개시 | Citigroup | Buy |
| 2016-01-20 | 개시 | Credit Suisse | Outperform |
모두보기
Coherus Oncology Inc 주식(CHRS)의 최신 뉴스
3 Penny Stocks With Market Caps Over $80M To Consider - simplywall.st
Coherus Oncology's (NASDAQ:CHRS) investors will be pleased with their solid 132% return over the last year - Yahoo Finance
Can Coherus Oncology Inc. (8C5) stock retain market dominanceMarket Activity Report & Long-Term Safe Investment Plans - newser.com
Will Coherus BioSciences Inc. stock recover faster than marketBuy Signal & Breakout Confirmation Trade Signals - newser.com
Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025 - The Manila Times
Coherus Oncology (NASDAQ: CHRS) schedules Nov. 6 results release and 5 p.m. ET call - Stock Titan
CapEx per share of Coherus Oncology, Inc. – DUS:8C5 - TradingView
Coherus Oncology, Inc. (NASDAQ:CHRS) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Coherus Oncology (CHRS) to Release Quarterly Earnings on Wednesday - MarketBeat
How Coherus Oncology Inc. (8C5) stock performs during market turbulenceLayoff News & Scalable Portfolio Growth Methods - newser.com
Despite shrinking by US$22m in the past week, Coherus Oncology (NASDAQ:CHRS) shareholders are still up 122% over 1 year - simplywall.st
Aug Ideas: How Coherus Oncology Inc. (8C5) stock performs during market turbulenceJuly 2025 Retail & Consistent Profit Trading Strategies - Fundação Cultural do Pará
Coherus Oncology (NASDAQ:CHRS) Given "Sell (D)" Rating at Weiss Ratings - MarketBeat
Will Coherus BioSciences Inc. stock deliver better than expected guidanceLayoff News & Real-Time Volume Surge Alerts - newser.com
Coherus Oncology (NASDAQ:CHRS) Share Price Crosses Above 200 Day Moving AverageHere's Why - MarketBeat
What analysts say about Coherus Oncology Inc 8C5 stockStock Buy Signals & Maximum Profit Growth - earlytimes.in
Will Coherus Oncology Inc. (8C5) stock benefit from infrastructure billPortfolio Risk Report & Risk Controlled Swing Trade Alerts - newser.com
Coherus Oncology to Participate in Upcoming Investor Conferences - The Manila Times
Will Coherus Oncology Inc. (8C5) stock outperform value peersBuy Signal & Community Verified Trade Alerts - newser.com
Lobbying Update: $80,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosed - Quiver Quantitative
What dividend safety rating applies to Coherus Oncology Inc. (8C5) stock2025 Volume Leaders & Expert Curated Trade Ideas - newser.com
Why Coherus Oncology Inc. (8C5) stock is trending on social media2025 Geopolitical Influence & Long Hold Capital Preservation Tips - newser.com
Guidance Update: Will Coherus Oncology Inc. (8C5) stock outperform value peersJuly 2025 Momentum & Long-Term Growth Portfolio Plans - nchmf.gov.vn
Stock Market Recap: Will Coherus Oncology Inc. (8C5) stock outperform value peersJuly 2025 Trends & Technical Pattern Recognition Alerts - Trung tâm Dự báo KTTV quốc gia
CHRS (Coherus Oncology) EBITDA Margin % : -405.39% (As of Jun. 2025) - GuruFocus
Coherus Oncology, Inc.Common Stock (Nasdaq:CHRS) Stock Quote | Oklahoma City NewsThe Oklahoman - FinancialContent
How Coherus Oncology Inc. (8C5) stock reacts to monetary easing2025 Dividend Review & Real-Time Market Trend Scan - newser.com
Coherus Oncology (NASDAQ:CHRS) Share Price Passes Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
What technical patterns form on Coherus Oncology Inc. (8C5) stock chartsMarket Sentiment Review & Weekly Return Optimization Plans - newser.com
Revenue per share of Coherus Oncology, Inc. – MUN:8C5 - TradingView
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals - inkl
How strong dollar benefits Coherus Oncology Inc. (8C5) stockJuly 2025 Price Swings & Weekly Hot Stock Watchlists - newser.com
Published on: 2025-10-06 04:13:27 - newser.com
Coherus Oncology Inc (CHRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.03%
0.32%
자본화:
|
볼륨(24시간):